Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C6H5O7.2Ca.Fe |
Molecular Weight | 514.2 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].[Ca++].[Fe++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
InChI
InChIKey=HSBFYEQJGSVAJW-UHFFFAOYSA-H
InChI=1S/2C6H8O7.2Ca.Fe/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502
Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Iron(II) gluconate (also known as a ferrous gluconate) is used in the treatment of hypochromic anemia. The real problem of iron therapy is not the theoretical utilization of iron, or the reticulocyte response, or even the daily increase of hemoglobin. These are important only as they indicate the return of the patients' blood to normal in a reasonably short time without undue inconvenience. Most patients suffering from hypochromic anemia respond well to most forms of iron when administered in adequate dosage. For the patients who cannot tolerate the usual iron compounds, it is important to have a medication which is effective and which causes minimum disturbance. Ferrous gluconate is such a medicament.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Ferro Sanol Duodenal Approved UseFerro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia. |
|||
PubMed
Title | Date | PubMed |
---|---|---|
Clinical appraisal of drugs with special reference to a new chelate hematinic. | 1957 Jul 11 |
|
[Historical notes on the therapy of depression]. | 1986 Nov 22 |
|
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe. | 1997 Oct |
|
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis. | 2011 Jun 10 |
|
Tolerability of different oral iron supplements: a systematic review. | 2013 Apr |
|
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows. | 2013 Jul |
|
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example. | 2017 Jul 5 |
|
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes. | 2017 Mar 13 |
|
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle. | 2017 May 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/ferrous-salts.html
Unknown
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB130515
Created by
admin on Fri Dec 15 15:31:52 GMT 2023 , Edited by admin on Fri Dec 15 15:31:52 GMT 2023
|
PRIMARY | |||
|
SUB13173MIG
Created by
admin on Fri Dec 15 15:31:52 GMT 2023 , Edited by admin on Fri Dec 15 15:31:52 GMT 2023
|
PRIMARY | |||
|
7600-56-8
Created by
admin on Fri Dec 15 15:31:52 GMT 2023 , Edited by admin on Fri Dec 15 15:31:52 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
4P1IZU59M5
Created by
admin on Fri Dec 15 15:31:52 GMT 2023 , Edited by admin on Fri Dec 15 15:31:52 GMT 2023
|
PRIMARY | |||
|
DTXSID60226906
Created by
admin on Fri Dec 15 15:31:52 GMT 2023 , Edited by admin on Fri Dec 15 15:31:52 GMT 2023
|
PRIMARY | |||
|
m611
Created by
admin on Fri Dec 15 15:31:52 GMT 2023 , Edited by admin on Fri Dec 15 15:31:52 GMT 2023
|
PRIMARY | |||
|
10097975
Created by
admin on Fri Dec 15 15:31:52 GMT 2023 , Edited by admin on Fri Dec 15 15:31:52 GMT 2023
|
PRIMARY | |||
|
258-703-5
Created by
admin on Fri Dec 15 15:31:52 GMT 2023 , Edited by admin on Fri Dec 15 15:31:52 GMT 2023
|
PRIMARY | |||
|
53684-61-0
Created by
admin on Fri Dec 15 15:31:52 GMT 2023 , Edited by admin on Fri Dec 15 15:31:52 GMT 2023
|
PRIMARY | |||
|
100000076565
Created by
admin on Fri Dec 15 15:31:52 GMT 2023 , Edited by admin on Fri Dec 15 15:31:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD